169544-41-6

Basic information

• Product Name: ETHYL 4-(4-CHLOROPHENYL)-3-METHYL-2,4-DIOXO-BUTYRATE
• Synonyms: ETHYL 4-(4-CHLOROPHENYL)-3-METHYL-2,4-DIOXO-BUTYRATE;4-CHLORO-METHYL-DIOXO BENZENEBUTANOIC ACID ETHYL ESTER;4-chloro-β-methyl-α,γ-dioxo-, ethyl ester;ethyl 4-(4-chlorophenyl)-3-Methyl-2,4-dioxobutanoate
• CAS NO: 169544-41-6
• Molecular Formula: C₁₃H₁₃ClO₄
• Molecular Weight: 268.69
• Product Categories: pharmacetical
• Mol File: 169544-41-6.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 397.6 °C at 760 mmHg
• Flash Point: 161.4 °C
• Appearance: /
• Density: 1.241g/cm³
• Vapor Pressure: 1.56E-06mmHg at 25°C
• Refractive Index: 1.522
• CAS DataBase Reference: ETHYL 4-(4-CHLOROPHENYL)-3-METHYL-2,4-DIOXO-BUTYRATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 4-(4-CHLOROPHENYL)-3-METHYL-2,4-DIOXO-BUTYRATE(169544-41-6)
• EPA Substance Registry System: ETHYL 4-(4-CHLOROPHENYL)-3-METHYL-2,4-DIOXO-BUTYRATE(169544-41-6)

Safety Data

• Hazardous Substances Data: 169544-41-6(Hazardous Substances Data)

Usage

General Description

ETHYL 4-(4-CHLOROPHENYL)-3-METHYL-2,4-DIOXO-BUTYRATE is a compound belonging to the class of organic chemicals known as butyrophenones. It is a white crystalline solid with a molecular formula C13H13ClO4 and a molecular weight of 268.69 g/mol. This chemical is commonly used in the synthesis of pharmaceuticals and as a building block in organic synthesis. It is important to handle this compound with caution, as it may present hazards if not properly managed.

InChI:InChI=1/C13H13ClO4/c1-3-18-13(17)12(16)8(2)11(15)9-4-6-10(14)7-5-9/h4-8H,3H2,1-2H3

Upstream product

• 6285-05-8 4'-chloropropiophenone 
• 95-92-1 oxalic acid diethyl ester 
• 64-17-5 ethanol 

Downstream Products

• 680187-02-4 1-(3-methyl-cyclohexyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxylic aci 
• 680187-03-5 1-(4-methyl-cyclohexyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxylic aci 
• 170937-37-8 4-(4-chlorophenyl)-2-[(2,4-dichlorophenyl)-hydrazono]-3-methyl-4-oxobutyric acid ethyl ester 
• 158941-22-1 ethyl 1-(2,4-dichlorophenyl)-4-methyl-5-(4-chlorophenyl)-1H-pyrazole-3-carboxylate 
• 1166391-03-2 (R)-ethyl 2-((S)-1-(4-chlorophenyl)-1-oxopropan-2-yl)-2-hydroxy-4-oxopentanoate 
• 1291068-11-5 C₂₀H₁₈ClF₃N₂O₃ 
• 1291068-10-4 C₁₈H₁₈ClN₃O₃ 
• 857855-71-1 [5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-yl]methanol 
• 913624-95-0 3-(bromomethyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole 
• 1291068-14-8 5-(4-chlorophenyl)-4-methyl-1-(pyridine-2-yl)-1H-pyrazole-3-carboxylic acid 
• 1291068-12-6 C₁₈H₁₆ClN₃O₂ 
• 1291068-13-7 C₂₀H₁₆ClF₃N₂O₂ 
• 1291068-15-9 5-(4-chlorophenyl)-4-methyl-1-[4-(trifluoromethyl)phenyl]-1H-pyrazole-3-carboxylic acid 
• 1291068-16-0 C₁₆H₁₁Cl₂N₃O 

Relevant articles and documents

MMPL3 INHIBITORS, COMPOSITIONS AND USES THEREOF

Disclosed are inhibitors of mycobacterial membrane protein MmpL3, compositions comprising the inhibitors, and methods of preparation and use thereof.

FUSED PYRAZOLE COMPOUNDS AS CB1R ANTAGONISTS AND USES THEREOF

The present invention relates to compounds of formula I, or isotopic forms, stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, polymorphs, prodrugs, S-oxides or N- oxides thereof, and processes for their preparation. The invention furt

Novel pyrazole derivatives as neutral CB1 antagonists with significant activity towards food intake

In spite of rimonabant's withdrawal from the European market due to its adverse effects, interest in the development of drugs based on CB1 antagonists is revamping on the basis of the peculiar properties of this class of compounds. In particular, new strategies have been proposed for the treatment of obesity and/or related risk factors through CB1 antagonists, i.e. by the development of selectively peripherally acting agents or by the identification of neutral CB1 antagonists. New compounds based on the lead CB1 antagonist/inverse agonist rimonabant have been synthesized with focus on obtaining neutral CB1 antagonists. Amongst the new derivatives described in this paper, the mixture of the two enantiomers (±)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-(2-cyclohexyl-1- hydroxyethyl)-4-methyl-1H-pyrazole ((±)-5), and compound 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[(Z)-2-cyclohexyl-1-fluorovinyl] -4-methyl-1H-pyrazole ((Z)-6), showed interesting pharmacological profiles. According to the preliminary pharmacological evaluation, these novel pyrazole derivatives showed in fact both neutral CB1 antagonism behaviour and significant in vivo activity towards food intake.